Cite
HARVARD Citation
Yang, J. et al. (n.d.). Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet oncology. 16 (7), pp. 830-838. [Online].